<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562445</url>
  </required_header>
  <id_info>
    <org_study_id>ISRRA-HDA2007</org_study_id>
    <secondary_id>EudraCT: 2007-002355-16</secondary_id>
    <nct_id>NCT00562445</nct_id>
  </id_info>
  <brief_title>Adrenal Insufficiency in Critical Emergencies in Digestive Diseases</brief_title>
  <official_title>Evaluation of the Incidence and Relevance of the Adrenal Insufficiency in Critical Emergencies in Digestive Diseases (GI Bleeding and Acute Pancreatitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study about the incidence of relative adrenal insufficiency in patients with
      cirrhosis and acute variceal bleeding; in patients with acute peptic gastrointestinal
      bleeding and without liver disease; and in patients with severe acute pancreatitis.

      This is a study using pharmaceutical specialties in the approved conditions of use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational, prospective, open-label, in-patient study, that includes patients with upper
      gastrointestinal bleeding of variceal or peptic origin, and in patients with severe acute
      pancreatitis.

      The adrenal function of every patient included will be evaluated in the first 24 hours of
      admission This assessment shall be performed using the corticotropin-stimulation short test
      (synacthen test), that includes serum and saliva determination of cortisol, in basal
      conditions and 30 and 60 minutes after the administration of 250 ug of corticotropin
      synthetic (Synacthen, Novartis Pharma AG, Basel, Switzerland).

      The cortisol levels will be determined by competitive immunoassay using direct
      chemoluminescence technology (Bayer Corporation, Pittsburgh, PA, USA).

      In patients with severe acute pancreatitis all of these determinations will be repeated at
      the third day of admission.

      Several other clinical and biochemical features will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">May 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative adrenal insufficiency</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic failure</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in portal hypertension.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for vasopressive drugs</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Digestive Diseases</condition>
  <condition>Adrenal Insufficiency</condition>
  <condition>Gastrointestinal Bleeding</condition>
  <condition>Variceal Bleeding</condition>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Peptic bleeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Portal hypertension bleeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Severe acute pancreatitis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to our centre that meet inclusion criteria and do not meet exclusion
        criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (one of the following):

          -  Presence of acute upper gastrointestinal bleeding (variceal or peptic) + presence of
             hypovolemic shock (defined as a systolic blood pressure &lt;100 mmHg coupled with a heart
             rate&gt; 100 ppm), or Hb &lt; 80 g / L;

          -  Acute pancreatitis (diagnosed by clinical, radiological and biochemical features)with
             severity criteria (At least one of the following: index of Ranson &gt; 3, APACHE II &gt; 8
             or CPR&gt; 120 mg/L, Balthazar CT grade E)

        Exclusion Criteria:

          -  Age &lt;18 years and &gt;80 years.

          -  Pregnancy.

          -  Patient refusal to participate in the study.

          -  Prior corticosteroids treatment(oral or topical).

          -  Treatment during the 30 days prior to inclusion with any of the following drugs:
             contraception, etomidate, ketoconazole, rifampin or phenytoin.

          -  History of cranial trauma or surgery.

          -  Any malignancy in treatment or progression.

          -  HIV infection.

          -  Prior known adrenal pathology.

          -  Patients not eligible to any active treatment because the existence of any clinical
             condition considered terminal.

          -  Patients with associated traumatic blood loss, or any other extraintestinal source of
             active bleeding.

          -  Burns.

          -  Patients who have been previously included in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candid Villanueva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candid Villanueva, MD</last_name>
    <phone>+34620955006</phone>
    <email>cvillanueva@santpau.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>HospitalSCSP</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candid Villanueva, MD</last_name>
      <phone>+34620955006</phone>
      <email>cvillanueva@sanrpau.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <last_update_submitted>November 21, 2007</last_update_submitted>
  <last_update_submitted_qc>November 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2007</last_update_posted>
  <keyword>Adrenal insufficiency</keyword>
  <keyword>GI bleeding</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Acute pancreatitis</keyword>
  <keyword>Critical emergencies in digestive diseases</keyword>
  <keyword>Severe acute pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

